For decades, the dream of fixing harmful mutations in mitochondrial DNA felt out of reach. Scientists have long known these ...

The FDA has approved Zegfrovy (sunvozertinib) for locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.

Replacing defective microglia can halt ALSP—a fatal neurodegenerative disease—in mice and humans, offering hope for broader brain therapies.

Peripheral artery disease (PAD) is a vascular disorder caused by occlusive atherosclerosis, which commonly impairs blood flow to the lower extremities. The prevalence of PAD is increasing globally ...

Microglia replacement therapy helps treat people with a rare genetic condition called ALSP, suggesting the approach could ...

Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) is a progressive neurological disease with an ...

DNA makes RNA, RNA makes protein, protein makes phenotype—was the guiding framework for understanding inheritance and disease ...

In a paper published last month, researchers at UT Southwestern Medical Center introduced lipid nanoparticles — hollow, fatty ...

Olaparib demonstrated activity in a phase 2 trial of patients who had advanced biliary tract cancer with homologous recombination repair (HRR) mutations. Results from this trial were presented at the ...

A groundbreaking study led by Prof. Bo Peng at Fudan University demonstrates that microglia replacement effectively halts the ...

A promising new study from the Knight Family DIAN-TU research group at Washington University School of Medicine has found that starting Alzheimer’s treatment years before symptoms begin could delay — ...

A research team led by Eske Willerslev, professor at the University of Copenhagen and the University of Cambridge, has recovered ancient DNA from 214 known human pathogens in prehistoric humans from ...